A b s t r a c t
Fine-needle aspiration (FNA) is an excellent test for the evaluation of thyroid nodules. 1 Repeated aspiration is commonly recommended and appears to change the overall risk of malignancy for nondiagnostic aspirates [2] [3] [4] [5] [6] [7] and may be useful to decrease the false-negative rate in laboratories with a relatively high false-negative rate after a single aspirate. [8] [9] [10] [11] [12] [13] [14] While some authors also suggest that repeated aspiration can be of value after an atypical aspirate, 2,15-17 histologic follow-up on patients with an atypical aspirate and a subsequent benign diagnosis is extremely limited.
Recently, some authors have proposed using the term risk of malignancy to better classify thyroid aspirate 1, 18, 19 because terminology that is commonly used in cytology reports for thyroid aspirates is not consistent in expressing that risk and can be misleading. [19] [20] [21] In addition, whether the risk of malignancy for some diagnoses is affected by the results of a prior benign aspirate is not clear. To assess this, I reviewed a large number of thyroid aspirates with repeated aspirates and subsequent resection and combined these results with those from intraoperative cytology and the literature.
Materials and Methods
All thyroid fine-needle aspirates interpreted at Baptist Hospital, Miami, FL, and Homestead Hospital, Homestead, FL, for the 13-year period October 1996 through November 2009 were reviewed and the results correlated with the results of histologic follow-up. For this study, cases were reclassified according to the most recent "state-of-thescience conference" system. 1 Upon completion of this activity you will be able to:
• recognize the risk of malignancy for a patient with an atypical thyroid fine-needle aspiration and a repeat aspirate that is negative.
• recognize that separate aspirates of the same thyroid nodule are most likely not independent events.
The ASCP is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The ASCP designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit ™ per article. This activity qualifies as an American Board of Pathology Maintenance of Certification Part II Self-Assessment Module.
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Questions appear on p 847. Exam is located at www.ascp.org/ajcpcme.
All aspirates were performed by clinicians. Approximately one third of aspirates were performed in clinician's offices without imaging studies. Between 2 and 8 passes were made. Two thirds of aspirates were performed in the radiology department of the Baptist Hospital, with the aid of ultrasound guidance and immediate evaluation. Direct smears were made in all cases, and all were alcohol fixed and stained with the Papanicolaou or H&E stain. If sufficient material was obtained, cell blocks were also made. Core needle biopsy was also available in approximately 400 cases.
Cases with an initial atypical diagnosis and an intraoperative smear at the time of resection were identified. All smears consisted of direct smears (not touch preparations) stained with H&E. I reviewed these smears in a blinded manner and also classified them per the most recent state-of-the-science conference system. 1 In this system, "atypical follicular cells" include a wide variety of features but can be grouped into 4 main categories: (1) aspirates with some microfollicles and/ or some nuclear enlargement and crowding but insufficient for a diagnosis of "suspicious" for a follicular neoplasm, (2) a scant aspirate composed almost exclusively of Hürthle cells but with insufficient cellularity to diagnose as suspicious for a Hürthle cell neoplasm, (3) an aspirate with a small group of cells with nuclear features of papillary carcinoma (pale chromatin, grooves, crowding but almost never inclusions) that are too focal or too poorly developed to diagnose as suspicious for papillary carcinoma, and (4) aspirates with atypia that is difficult to further define, which is usually cytologic rather than architectural atypia, and may be secondary to poor preservation.
For the literature review, only series in which the methods clearly showed that the definition of atypical was similar to that used in the state-of-the-science conference system 1 were included. For histologic follow-up, when papillary "microcarcinomas" were identified (<1 cm) and unrelated to the initial aspirate, the cases were counted as benign.
Categorical analysis was done using a 2-tailed χ 2 test. Continuous data were analyzed by using a 2-tailed t test. A P value of .05 was considered significant.
Results
During the study period, a total of 7,089 cases were aspirated, and 1,331 resections were performed ❚Table 1❚. A total of 163 (12.2% of cases with resection) repeated aspirations were performed.
There was a total of 15 aspirates that were atypical after a benign aspirate and had subsequent excision ❚Table 2❚. These nodules ranged in size from 0.6 to 3.9 cm (mean, 1.8 ± 1.0 cm). Of these cases, 2 (13%) were malignant on excision. The literature for histologic follow-up for an atypical aspiration after an initial benign aspiration is also shown in Table  2 . Overall, 11 (15%) of 75 cases with a subsequent atypical diagnosis were malignant.
I sought to determine if there was any increase in malignancy over time in the study data or in the literature that would suggest that the carcinomas detected (Table 2) were the result of a change in the nodule rather than sampling of different areas of the nodule. In the study data, there was a total of 6 false-negative cases for the 7,089 aspirates, with surgical excision ranging from less than 1 year to 4 years after the aspirations. The false-negative rate decreased from 0.13% (3/2,361) in the first 2 years to 0.06% (3/4,728) after 2 years. Similarly, there were 3 false-negatives in the 49 aspirates that were repeated, including 2 (9%) of 23 in the first year and 1 (4%) of 26 more than 1 year later. In the literature, the time frame for cases with a benign aspirate followed by an atypical aspirate was 7 years. In the studies with relevant data, the false-negative rate consistently decreased from the first half of the study to the second half of 2 studies. 9, 12 ❚Table 3❚ shows the follow-up for repeated aspirations in the study laboratories for cases initially diagnosed as atypical follicular cells. Of these, 50% were malignant, although only 8 cases were found.
❚Table 4❚ 2, 13, 22 shows the follow-up for cases with an initial atypical diagnosis on FNA and subsequent intraoperative cytology. The size of these cases ranged from 0.8 to 8 cm (mean, 1.8 ± 1.0 cm). The size of the intraoperative cases was not significantly different from the cases that had an initial benign aspirate and a subsequent atypical aspirate (Table 2 ; P = .55). It also shows the results in the literature for cases with an initial atypical aspirate and a repeated FNA combined with results for repeated aspiration and intraoperative cytology. In 32 patients, there was subsequent benign cytology, and 3 (9%) of these were malignant.
Since the data suggest that different results in the second aspirate after a benign diagnosis are the result of sampling rather than a change in the nature of the nodule, this would suggest that the order of the aspirates (benign then atypical or atypical then benign) would not matter. Supporting this, there was no significant difference in the rate of malignancy (15% vs 9%; P = .30) for these 2 groups.
I also sought to determine if the type of specimen (FNA vs intraoperative smear) was significant. The risk of malignancy for 2 FNA samples (benign and atypical, either order, 11/83 [13%]) was not significantly different from the risk of an atypical fine-needle aspirate followed by a benign intraoperative smear (3/26 [12%]; P = .82).
Using histologic follow-up as the "gold standard" and limiting the study to series with at least 300 patients for benign aspirates, the risk of malignancy for a single aspiration was 2.8% for a benign diagnosis and 26.77% for an atypical diagnosis ❚Table 5❚. 2, 13, 15, 16, 21, [23] [24] [25] [26] [27] [28] Since the order did not appear to matter, I combined benign then atypical cases with atypical then benign cases and compared them with the risk of malignancy for a single aspirate ( 
Discussion
I was motivated to pursue this study by 3 factors: (1) the dearth of histologic follow-up for a recommendation to repeat aspirations in the setting of atypical aspirates of the thyroid in the most recent state-of-the-science conference, (2) the belief by most of our endocrinologists and surgeons at our hospitals and some authors in the literature that patients with atypical aspirates should go to surgery rather than have repeated aspiration since the risk of malignancy for these patients is very similar to that of patients with a diagnosis of suspicious for a follicular or Hürthle cell neoplasm, 18, 21 and (3) the idea that repeated aspirations of the same nodule are likely to not be independent events, as evidenced by the consistent finding that repeatedly benign aspirates consistently lower the overall false-negative rate. 9, 11, 13, 29 The major problem with evaluating the risk of malignancy for patients with an atypical and a subsequent benign aspirate is the lack of histologic follow-up; as shown in the tables, there are only 8 such cases in the literature, including the present study. Although there is substantial clinical follow-up of such patients, this is of limited utility since patients with these carcinomas usually have an excellent prognosis. Indeed, none of the patients who had false-negative biopsy results in this series developed metastases, even though in some cases it took up to 4 years to identify the carcinoma.
I took 2 separate and unique approaches to this problem. First, I examined the risk of malignancy in patients with repeated aspirations after a benign diagnosis. I believe this is relevant because the study data and the data in the literature do not show any increase in malignancy rate with time, and, thus, changes in diagnoses likely represent differences in sampling the nodule (or in some cases, tissue around it) rather than changes in the nature of the nodule over time. If this is true, then I would expect the risk of malignancy in patients with a benign aspirate followed by an atypical aspirate to be similar to that of patients with an atypical aspirate followed by a benign aspirate. The study data support this contention. I therefore felt justified in combining these 2 groups of patients.
Second, I gathered data on patients with an atypical aspirate followed by a benign aspirate with surgical follow-up. As in previous studies, such cases are extremely rare since many endocrinologists who believe in repeated aspiration for an atypical aspirate elect to follow up rather than perform excision in such cases. However, I also included patients with atypical aspirates who had an intraoperative smear at the time of frozen section. The study also demonstrated that these patients did not have a significantly different risk of malignancy from patients with a benign then an atypical aspirate. I therefore felt justified in combining these 2 groups of patients. This allowed generation of a significantly greater number of cases for more meaningful comparisons.
Finally, when the study data are combined with the data in the literature, it appears that aspirations of the same nodule are not independent events. The risk of malignancy for patients with a benign and an atypical aspirate (in either order) is significantly higher than that for patients with a single benign aspirate and significantly lower than that for patients with a single atypical aspirate. Patients with a benign and an atypical aspirate likely represent a subset of all patients who have nodules that have variation in their composition, and this variation is identified by repeated aspiration. While the overall risk of malignancy for these patients is not fully known since only a subset of all patients with benign or atypical aspirates undergo resection, 18 the relative risks reported herein remain valid.
Despite my analysis that the risk of malignancy for intraoperative cytology is similar to that of FNA, I acknowledge that intraoperative cytology is different from FNA. In the hands of physicians at the study institutions, every intraoperative smear was excellent and did not have preparation artifacts or scant cellularity. As such, they likely represent "ideal" aspirate specimens, and this may have biased the results. If air-drying artifact and scant cellularity were present in these cases, it is possible that more of them would have been interpreted as atypical rather than benign. However, this would likely result in an increased rather than a decreased risk of malignancy for a repeated negative aspirate.
It is also possible that the results in this study are affected by clinician bias. For example, patients with an atypical aspirate who are sent for reaspiration may represent a group of patients who are at lower risk of malignancy (eg, smaller size, younger age) than patients who are sent for resection. This might explain why the risk of malignancy for these patients is less than that for a single atypical aspirate alone. However, analysis of intraoperative specimens, which presumably represent patients at higher risk based on clinical findings, does not support this. On the other hand, it is possible that clinicians may select a group of patients who are at higher risk for malignancy than all patients with a single atypical aspirate for reaspiration. However, again, the study data comparing the risk of these 2 groups does not support this.
Should patients with an atypical diagnosis then undergo repeated aspiration? This question ultimately depends on exactly what risk is necessary to elect to have surgery for a nodule. The study data strongly suggest that these patients have higher risk of malignancy than patients with a single benign aspirate. Whether this risk is low enough to simply follow up the patients is not known.
How then should cytologists convey this risk? The current practice of simply diagnosing every case independently does not adequately address this. I believe that when a repeated aspirate is performed and the cytologist has knowledge of the prior result, it should be incumbent on that cytologist to convey that the risk of malignancy for a benign or an atypical diagnosis is altered by that prior aspirate, and an estimate of that risk should be given. Otherwise, cytologists are once again using the language in the cytology report inconsistently and using the same words to convey 2 significantly different risks. 19 I have shown that repeated thyroid aspirations that are atypical and then benign are most likely due to sampling different regions within a nodule rather than changes in that nodule over time and are not independent events. The results of prior aspirations significantly alter the risk conferred by subsequent diagnoses. Patients with an atypical and a benign diagnosis have a risk of malignancy significantly higher than a single benign diagnosis and significantly lower than a single atypical diagnosis. Cytologists should strive to better communicate this risk to clinicians and patients.
